Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Haemonetics Corp. diskutieren

Haemonetics Corp.

WKN: 881782 / Symbol: HAE / Name: Haemonetics / Aktie / Ausrüstung & Versorgung / Mid Cap /

62,50 €
-

Haemonetics Co. (NYSE: HAE) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for HAE provided by MarketBeat

Haemonetics Co. (NYSE: HAE) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for HAE provided by MarketBeat

Haemonetics Co. (NYSE: HAE) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for HAE provided by MarketBeat

Haemonetics Co. (NYSE: HAE) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -18,40 %
Kursziel 97,80
Veränderung
Endet am 03.11.24

Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Barrington Research from $114.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -11,36 %
Kursziel 97,90
Veränderung
Endet am 13.02.25

Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $105.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -34,39 %
Kursziel 98,71
Veränderung
Endet am 12.04.25

Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $105.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -29,38 %
Kursziel 99,33
Veränderung
Endet am 10.05.25

Haemonetics Co. (NYSE: HAE) had its price target raised by analysts at Barrington Research from $105.00 to $107.00. They now have an "outperform" rating on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,68 %
Kursziel 103,42
Veränderung
Endet am 12.06.25

Haemonetics Co. (NYSE: HAE) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $112.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -6,02 %
Kursziel 101,52
Veränderung
Endet am 10.09.25

Haemonetics Co. (NYSE: HAE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $112.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,41 %
Kursziel 104,48
Veränderung
Endet am 13.09.25

Haemonetics Co. (NYSE: HAE) is now covered by analysts at CL King. They set a "buy" rating and a $116.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,09 %
Kursziel 97,01
Veränderung
Endet am 23.09.25

Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -22,36 %
Kursziel 100,71
Veränderung
Endet am 08.11.25

Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -25,60 %
Kursziel 106,41
Veränderung
Endet am 15.11.25

Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $112.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -22,36 %
Kursziel 106,36
Veränderung
Endet am 03.12.25

Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $112.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) -20,38 %
Kursziel 102,93
Veränderung
Endet am 04.12.25

Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,65 %
Kursziel 104,18
Veränderung
Endet am 07.02.26

Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Needham & Company LLC from $112.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Sell
Rendite (%) 9,65 %
Kursziel 65,59
Veränderung
Endet am 07.02.26

Haemonetics Co. (NYSE: HAE) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $68.00 price target on the stock, down previously from $95.00.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,65 %
Kursziel 91,64
Veränderung
Endet am 07.02.26

Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Barrington Research from $108.00 to $95.00. They now have an "outperform" rating on the stock.
Ratings data for HAE provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,65 %
Kursziel 111,41
Veränderung
Endet am 07.02.26

Haemonetics Co. (NYSE: HAE) had its "strong-buy" rating re-affirmed by analysts at Raymond James. They now have a $115.00 price target on the stock, down previously from $120.00.
Ratings data for HAE provided by MarketBeat